We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





Rapid Antigen Testing for SARS-CoV-2 Could Effectively Control COVID-19 Outbreak, Finds Study

By LabMedica International staff writers
Posted on 30 Aug 2021
Print article
Illustration
Illustration
Rapid COVID-19 antigen tests that permit new cases to isolate immediately can be important surveillance tools and effectively control COVID-19 outbreaks, according to a longitudinal comparison between antigen tests performed at home and quantitative real-time polymerase chain reaction (qRT-PCR).

Researchers at E25Bio, Inc. (Boston, MA, USA), LabCentral, Inc. (Boston, MA, USA), Harvard T. H. Chan School of Public Health (Boston, MA, USA), Mount Sinai School of Medicine (New York, NY, USA), and BioInnovation Labs, LLC (Cambridge, MA, USA) sought to validate the effectiveness of direct antigen rapid tests (DARTs) and to test whether at-home testing with DART could prevent the spread of SARS-CoV-2 in a co-working environment. The team conducted a study of high-frequency testing using inexpensive, at-home, semi-quantitative, DARTs and compared their performance with that of qRT-PCR on self-collected nasal specimens.

For the study, a total of 257 participants were enrolled who self-collected nasal swab specimens twice weekly at home during a six-month period. DART was performed at home, and the findings were compared with laboratory qRT-PCR tests. A total of 2,951 pairs of nasal swabs were self-collected by participants and tested by qRT-PCR and DART. The researchers found that that twice-weekly surveillance with DART detected infections in 15 individuals, with 96.3% sensitivity on days 0 through 3 of symptoms. Detection on day 3 is almost as effective as detection on day 1 for reducing the incidence of COVID-19, if 75% of a population is surveilled. The prevalence of disease dictates the frequency of testing and its effectiveness for controlling potential outbreaks.

COVID-19 outbreak management has been hindered by high transmission rates and limitations in testing capacity. Effective public health tools are needed for rapid and early detection. The current diagnostic standard is qRT-PCR, although its cost and long turnaround times limit its utility for widespread surveillance. However, frequent at-home testing with DART allows infected individuals to be identified and quarantined immediately. Such surveillance can prevent viral transmission in in-person work environments or other social settings, effectively controlling COVID-19 outbreaks, according to the researchers.

Related Links:
E25Bio, Inc.
LabCentral, Inc.
Harvard T. H. Chan School of Public Health
Mount Sinai School of Medicine
BioInnovation Labs, LLC


Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
New
ELISA Mini Workstation
Crocodile 5-in-one
New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Gold Supplier
Desktop Urine Analyzer
MONOZYME TX2000

Print article

Channels

Hematology

view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more

Immunology

view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.